Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: A randomised trial
BJOG: An International Journal of Obstetrics and Gynaecology, Volume 107, No. 4, Year 2000
Notification
URL copied to clipboard!
Description
Objectives To compare the efficacy of two different regimens of mifepristone followed by misoprostol for medical abortion in women with menstrual delay of ≤ 35 days. Design Double-blind, randomised controlled trial. Setting Seventeen centres internationally. Participants We enrolled 1589 healthy pregnant women with menstrual delay of ≤ 35 days who were requesting nonsurgical abortion. Interventions Within gestational age strata, we randomly assigned women to receive a single oral dose of mifepristone, either 200 mg or 600 mg, followed in 48 h by misoprostol 400 μg by mouth. We concealed the allocation assignments from investigators and participants and maintained double-blinding throughout the study. Main outcome measures Complete abortion was the principal outcome measure. We also compared rates of side effects such as abdominal pain. Results The complete abortion rate with the lower dose of mifepristone was similar to that with the higher dose (89.3%vs 88.1%) The crude relative risk of failure to achieve complete abortion with the 200 mg dose compared with the 600 mg dose was 0.9 (95% CI 0.7 to 1.2). The likelihood of complete abortion was inversely related to gestational age, although this finding is exploratory in nature. Among failures the percentage of women with continuing pregnancies increased from 1.4% at menstrual delay of two weeks or less to 9.0% when the delay was 4–5 weeks. Low efficacy led to stopping enrolment at 29 to 35 days' menstrual delay. Stopping criteria were also met at completion of the study in the group with 22–28 days' menstrual delay. No significant differences emerged in the frequency of side effects between the two mifepristone groups. Conclusions Both regimens had similar efficacy. Women with a menstrual delay of four to five weeks had twice the risk of failure to abort compared with those who received treatment within two weeks of the expected menses. The efficacy of the mifepristone-prostaglandin regimen was not reduced by decreasing the dose of mifepristone from 600 mg to 200 mg. The regimens of 600 mg or 200 mg of mifepristone, followed by a single oral dose of misoprostol 400 μg 48 hours later, were not sufficiently efficient in inducing abortion when the menstrual delay was > 21 days. © 2000 Wiley. All rights reserved.
Authors & Co-Authors
Wu, Y. M.
China, Beijing
Peking Union Medical College Hospital
Gomez-Alzugaray, M.
Cuba, Havana
Instituto Nacional de Endocrinologia y Enfermedades Metabolicas
Haukkamaa, Maija
Finland, Helsinki
Helsinki University Hospital
Ngoc, Nguyen Thi Nhu
Viet Nam, Ho Chi Minh City
Hung Vuong Hospital
Ho, Pak Chung
Hong Kong, Hong Kong
The University of Hong Kong
Pretnar-Darovec, Alenka
Slovenia, Ljubljana
University Department of Obstetrics and Gynaecology
Healy, David Lindsay
Australia, Clayton
Monash University
Sotnikova, E.
Russian Federation, Moscow
Nationa Medical Research Center Obsterics, Gynecology and Perinatology the Name of Academician V.i. Kulakov
Shah, Rashmi S.
India, New Delhi
Indian Council of Medical Research
Pavlova, N. G.
Russian Federation, Saint Petersburg
D.o. Ott Research Institute of Obstetrics and Gynecology Rams
Chen, Junkang
China, Shanghai
Shanghai Institute of Planned Parenthood Research
Song, Si
China, Shanghai
Shanghai Institute of Planned Parenthood Research
Bygdeman, Marc S.
Sweden, Stockholm
Karolinska Universitetssjukhuset
Kovács, László G.
Hungary, Szeged
Szegedi Tudományegyetem Általános Orvostudományi Kar
Khomassuridze, Archil G.
Georgia, Tbilisi
Zhordania Institute of Human Reproduction
Song, L. J.
China, Tianjin
Tianjin Municipal Research Institute for Family Planning
Hamzaoui, R.
Tunisia, Tunis
Centre D’etude et de Recherche en Reproduction Humaine de L’onfp
Alexaniants, S.
Armenia, Yerevan
Armenian Research Centre of Maternal and Child Health Protection
van Look, Paul F.A.
Switzerland, Geneva
Organisation Mondiale de la Santé
von Hertzen, Helena
Switzerland, Geneva
Organisation Mondiale de la Santé
Piaggio, Gilda Gp
Switzerland, Geneva
Organisation Mondiale de la Santé
Peregoudov, Alexandre
Switzerland, Geneva
Organisation Mondiale de la Santé
Vucurevic, M.
Switzerland, Geneva
Organisation Mondiale de la Santé
Grimes, David A.
United States, San Francisco
University of California, San Francisco
Statistics
Citations: 153
Authors: 24
Affiliations: 19
Identifiers
Doi:
10.1111/j.1471-0528.2000.tb13273.x
ISSN:
14700328
e-ISSN:
14710528
Research Areas
Disability
Health System And Policy
Sexual And Reproductive Health
Study Design
Randomised Control Trial
Exploratory Study
Participants Gender
Female